L3VLUP
ProSign in

INCY · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

INCYJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • INCY
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterINCYJNJ
Q3 202016 holders, $5.4bn30 holders, $26.2bn
Q4 202015 holders, $5.1bn32 holders, $26.6bn
Q1 202113 holders, $4.6bn31 holders, $25.3bn
Q2 202113 holders, $5.3bn37 holders, $25.6bn
Q3 202115 holders, $3.9bn40 holders, $24.1bn
Q4 202121 holders, $3.6bn33 holders, $25.2bn
Q1 202217 holders, $3.5bn35 holders, $28.2bn
Q2 202218 holders, $3.6bn33 holders, $26.9bn
Q3 202217 holders, $3.0bn36 holders, $25.4bn
Q4 202221 holders, $3.5bn35 holders, $27.6bn
Q1 202321 holders, $2.8bn42 holders, $24.5bn
Q2 202323 holders, $2.7bn38 holders, $25.0bn
Q3 202323 holders, $2.5bn37 holders, $18.9bn
Q4 202319 holders, $2.5bn31 holders, $19.0bn
Q1 202420 holders, $2.1bn32 holders, $19.7bn
Q2 202418 holders, $2.1bn35 holders, $20.4bn
Q3 202416 holders, $2.2bn28 holders, $22.3bn
Q4 202414 holders, $2.0bn37 holders, $20.4bn
Q1 202513 holders, $1.9bn32 holders, $20.5bn
Q2 202515 holders, $2.6bn31 holders, $18.4bn
Q3 202513 holders, $3.0bn32 holders, $23.7bn
Q4 202513 holders, $3.5bn29 holders, $27.8bn
Q1 202613 holders, $3.4bn34 holders, $35.6bn
Q2 202615 holders, $4.4bn33 holders, $39.1bn
INCY

Incyte Corp

Holders
14
Reported value
$2.0bn
Buyers
4
Sellers
9

Breadth -5 among 94 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
37
Reported value
$20.4bn
Buyers
23
Sellers
12

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only INCY (3)

ARK Investment Management LLC, Brevan Howard Capital Management LP, Caxton Associates LLP

Only JNJ (26)

AllianceBernstein LP, Arrowstreet Capital LP, Balyasny Asset Management LLC, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Squarepoint Ops LLC, Susquehanna International Group LLP, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Verition Fund Management LLC, Voloridge Investment Management LLC, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →